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Fluorescence lifetime imaging microscopy
A B S T R A C T
In response to physiological and artificial stimuli, cells generate nano-scale extracellular vesicles (EVs) by en-
capsulating biomolecules in plasma membrane-derived phospholipid envelopes. These vesicles are released to
bodily fluids, hence acting as powerful endogenous mediators in intercellular signaling. EVs provide a com-
pelling alternative for biomarker discovery and targeted drug delivery, but their kinetics and dynamics while
interacting with living cells are poorly understood. Here we introduce a novel method, fluorescence lifetime
imaging microscopy (FLIM) to investigate these interaction attributes. By FLIM, we show distinct cellular uptake
mechanisms of different EV subtypes, exosomes and microvesicles, loaded with anti-cancer agent, paclitaxel. We
demonstrate differences in intracellular behavior and drug release profiles of paclitaxel-containing EVs.
Exosomes seem to deliver the drug mostly by endocytosis while microvesicles enter the cells by both endocytosis
and fusion with cell membrane. This research offers a new real-time method to investigate EV kinetics with
living cells, and it is a potential advancement to complement the existing techniques. The findings of this study
improve the current knowledge in exploiting EVs as next-generation targeted drug delivery systems.
1. Introduction
Extracellular vesicles (EV) are a heterogeneous group of phospho-
lipid bilayer-bound vesicles secreted by prokaryotic and eukaryotic
cells [1, 2]. EVs can be classified with respect to their biogenesis
pathways and various biochemical and –physical attributes into three
major groups, although several other types of EVs exist as well [3–5].
Exosomes (EXOs) are a sub-group of EVs generated by reverse budding
from the peripheral membrane of multivesicular bodies (MVB) within
endosomal network and released when MVBs fuse with the plasma
membrane. The size of EXOs in MVBs before secretion varies in the
range 40–120 nm. Microvesicles (MV) are derivatives of plasma mem-
brane budding with wider size distribution of approximately
50–1000 nm. Lastly, apoptotic vesicles (APO) are EVs of up to 2000 nm
in diameter and originating from plasma membrane shedding of
apoptotic cells [6]. We delimit the debate herein to EXOs and MVs as
they are the two prominent EV sub-populations under immense
investigation throughout the field, and our present work focuses on
characterizing the sub-cellular mobility of these EV types.
Virtually all cells secrete EVs at normal physiological conditions as
well as during pathological states. EVs are pertinent mediators e.g. in
immune system responses [7, 8], cancer progression and metastasis
[9–13], infections [14–16] and inflammatory diseases [17]. EVs do not
arbitrarily distribute in bodily fluids but they deliver nucleic acids,
proteins, lipids and various small molecules via intercellular pathways
to specific cellular targets. Due to their biological origin, EVs possess a
unique natural content that allows for overcoming the known limita-
tions of artificial liposomal drug carriers, such as potential liver toxicity
or immunogenicity as well as targeting issues [18, 19]. Once delivered,
the EV cargo can modulate various biological functions in target cells
according to the payload instructions. These features make EVs a pro-
mising alternative to conventional liposome-based targeted drug de-
livery. They can be loaded with small or macromolecular drugs to ac-
complish specific therapeutic effects [20–22]. When used as drug
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delivery carriers, EVs' natural biogenesis and delivery mechanisms
could be exploited in combination with surface chemistry modification
to achieve desired pharmacokinetic distribution, metabolization and
elimination profiles. However, the current mechanistic understanding
of EV-mediated drug delivery is somewhat limited and there is an
unmet need to develop novel methodologies to overcome these lim-
itations. Most existing EV characterization techniques are best suited
for investigating their biochemical contents [23–32], not for providing
information on the EVs' kinetic and dynamic properties. Only confocal
microscopy has been utilized to track the cellular uptake of EVs on a
sub-cellular level [33], while flow cytometry (FC) has been employed to
estimate the bulk uptake kinetics of EVs [34, 35], however FC cannot be
used to distinguish between intracellular and surface-bound EVs. Thus,
an intriguing question still remains unanswered: how to obtain sub-
cellular insights in real time into the EV kinetics in the case of cellular
uptake?
Fluorescence lifetime imaging microscopy (FLIM) is a technique to
map the spatial distribution of excited state lifetimes in microscopic
samples. Being minimally invasive, the method is widely used nowa-
days for biomedical applications, particularly for gaining information
on molecular dynamics and interactions in single living cells [36–38].
Conventional fluorescence confocal (one or two-photon excitation)
techniques use steady-state fluorescence intensity measurements to
produce corresponding two or three-dimensional images. However,
fluorescence intensity is strongly affected by a variety of environmental
influences, such as strong background fluorescence of the living sys-
tems, quenching by other molecules, aggregation, energy transfer, and
refractive index effects. This makes it difficult to interpret and quantify
the intensity-based data, especially in complex samples such as cells or
tissues. In FLIM the fluorescence lifetime (τ) of a probe molecule is
measured as the rate of emission decay [39, 40] and the differences in
the probe fluorescence decay times provide the contrast mechanism for
FLIM images [41, 42]. The advantage of using FLIM in complex systems
is that the calculated fluorescence lifetimes can provide significantly
more information than the intensities. Since the excited state lifetime
depends on the local physicochemical environment of the fluorophore,
it is used for sensing inter- and intramolecular processes in living cells,
such as protein and DNA binding events [43, 44], changes in pH [45],
local viscosities [46], and the presence of such lifetime quenchers as
ions or oxygen [47, 48]. FLIM delivers information about the en-
vironmental change around the fluorescent probe even when it mainly
remains in the same spatial location (e.g. inside the cell) and its
fluorescence intensity holds constant. Notably, the emission is an in-
herent property of the fluorophore, and therefore the fluorescence
lifetime is not affected by the change in probe concentration, photo-
bleaching, or light scattering. Additionally, the excited state lifetime is
not influenced by internal settings of the instrument such as laser in-
tensity or detector gain. Autofluorescence of biological structures such
as mitochondria and lysosomes can be almost avoided by time-corre-
lated single photon counting, i.e. TCSPC-based FLIM systems, utilized in
the current study.
Only a few successful applications of excited state lifetime micro-
scopy to monitor cellular uptake and release of a drug from the poly-
plexes [49, 50], and teranostics [51], have been recently reported. As
yet, FLIM has not been utilized to investigate neither the EV cell-uptake
processes as a function of time nor to investigate the intracellular
trafficking of EVs. In this study, an anti-cancer drug, paclitaxel (Ptx),
covalently labeled with Oregon Green (OG) fluorophore and loaded
into EXOs or MVs is used to probe for various cellular uptake stages and
intracellular trafficking of Ptx-OG and EV-Ptx-OG. Ptx-OG has been
previously used in studying the intracellular kinetics of drugs, and Ptx-
OG interaction with the microtubule network [52]. EV-mediated de-
livery of Ptx-OG has also been demonstrated earlier [35, 53–55] but the
underlying sub-cellular mechanisms have not been meticulously ex-
plored. According to previous reports, EV uptake by recipient cells
potentially occurs via endocytic pathway, phagocytosis,
micropinocytosis [33, 56], or, through a fusion process with the plasma
membrane [57].
Paclitaxel belongs to the group of taxanes known to target micro-
tubules, interacting with β-tubulin and consequently distracting mi-
crotubule dynamics by preventing their disassembly [58, 59]. On ac-
count of this, the microtubule network is expected to be labeled by Ptx-
OG regardless the type of carrier (EXOs or MVs). As the EVs are pro-
cessed in the endosomal network, their cargo has many alternative
fates, including lysosomal degradation, recycling to the plasma mem-
brane, exocytosis via the exosomes of the multivesicular bodies and
additional intracellular trafficking at the trans-Golgi network, from
which Ptx-OG could end up virtually anywhere in the cell, including the
Bcl-2 expressing organs [60]. However, as EVs have also been shown to
be able to fuse with the plasma membrane of the cell [61], in this case
the delivery of Ptx-OG should appear similar to the delivery pattern of
free Ptx-OG, since both would enter the cell through diffusion from the
plasma membrane.
The concept of the study is illustrated in Scheme 1. Using FLIM for
live-cell imaging, we demonstrate that the Ptx-OG trafficking in pros-
tate cancer (PC) cells indeed utilize different intracellular pathways
depending on the delivery system it is loaded into. Furthermore, we
show that the intracellular release of Ptx-OG from the EV-carriers can
be observed by monitoring OG fluorescence lifetime. We envisage that
this FLIM-based platform may provide a powerful tool to study both the
intracellular trafficking of EVs and Ptx-OG. In addition, the obtained
results can open new perspectives for experts working with targeted
drug delivery development and controlled drug release.
2. Materials and methods
2.1. Cell culturing
Gibco™ (ThermoFisher Scientific, Massachusetts, USA) reagents
were used for cell culturing. For live-cell imaging human prostate
cancer cell line PC-3 cells (ATCC, Virginia, USA) were cultured in T-75
flasks, using 10ml of Ham's F-12 K (Kaighn's) Medium with 10% (v/v)
FBS and 100 units/ml penicillin/ streptomycin. For PC-3 EV production
CELLine 1000 CE bioreactor flasks (Wheaton, New Jersey, USA) were
used. The bioreactor upper compartment was filled with 750ml of
Scheme 1. Experimental design and concept. Vesicles of different sizes illus-
trate the size heterogeneity of EV populations used in this study (SI Fig. S3A).
Colors of Ptx-OG in the scheme (red, yellow and green) correspond to the color
scale of FLIM images 2.0 ns 4.5 ns. Solid arrows represent con-
firmed trafficking paths of the Ptx-OG-EVs and Ptx-OG inside the cell, dashed
arrows are assumed pathways that require additional studies to prove.
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Ham's F-12 K (Kaighn's) Medium with 10% (v/v) FBS, supplemented to
a final concentration of 4.5 g/l glucose solution, and 100 units/ml pe-
nicillin/streptomycin. 15ml of corresponding Ham's culture medium
without FBS was used in the bioreactor's cell compartment to avoid FBS
derived EVs. The culture medium containing EVs was collected once a
week from the bioreactor's cell compartment, the cell compartment was
washed three times with 15ml of fresh medium to detach the excessive
amount of cells, and 750ml of fresh culture medium was changed to the
upper compartment. The cells were cultured at +37 °C, 5% CO2, 95%
relative humidity.
2.2. EV isolation
EV isolation was performed using, differential ultracentrifugation.
In brief, the medium was collected from the bioreactor's cell compart-
ment, and consequently buoyant cells, cell fragments and big apoptotic
vesicles were removed by centrifuging with Centrifuge 5810 R desktop
centrifuge (Eppendorf, Hamburg, Germany) at 2500g for 25min,
+4 °C. Next, MVs were extracted from the supernatant by centrifuging
with Beckman Coulter Optima LE-80 K ultracentrifuge, Type 50.2 Ti
rotor (Coulter, California, USA) at 20000g for 1 h, +4 °C. EXOs were
isolated from the supernatant by centrifuging with the same ultra-
centrifuge setting at 110000g for 2 h, +4 °C. Lastly, the supernatant
was removed also from the EXO pellet. Both, the MV and EXO pellets
were allowed to detach from the centrifuge tubes in 100 μl of DPBS
buffer (ThermoFisher Scientific, Massachusetts, USA) overnight at
+4 °C, followed by further purification in an iodixanol (Optiprep™,
Sigma Aldrich) density gradient. In the current study we discriminate
the EV populations according to the centrifugal force used for the iso-
lation of each fraction and call them herein 20 K MVs and 110 K EXOs.
2.3. Iodixanol density gradient centrifugation
Iodixanol was buffered with DPBS and used to prepare a stepwise
density gradient. In order to determine the buoyant density of EVs, the
EV pellets produced in Section 2.2 were mixed with iodixanol into a
final concentration of 40% with final volume of 2ml and loaded at the
bottom of a discontinuous iodixanol gradient prepared by overlayering
30%, 20% and 10% iodixanol 2ml each and filling the rest of the
centrifuge tube with buffer. The samples were then ultracentrifuged for
18.5 h with 200,000 g at +4 °C. 1ml fractions were then collected from
the top, discarding the bottom 2ml. The EV-containing fractions were
identified with NTA analysis, pooled and iodixanol was removed by
diluting in 15ml total volume of cold DPBS followed by serial ultra-
filtration with Amicon Ultra-15 ultrafiltration units at +4 °C.
A simplified approach with iodixanol gradient was used for sample
preparation in FLIM experiments. Here, EV-pellets were loaded on top
of a gradient prepared by overlaying 700 μl of 10% iodixanol on top of
300 μl of 30% iodixanol in 1.5ml ultracentrifuge tubes. The samples
were then ultracentrifuged in rotor TLA-55 with Optima MAX-XP ul-
tracentrifuge for three hours with 170,000 g at +4 °C. The resulting
visible EV-band in the 10% and 30% interphase was then collected and
iodixanol was removed by ultrafiltration as described above.
2.4. Nanoparticle tracking analysis (NTA)
The particle concentrations and size distributions of 20 K MVs and
110 K EXOs were analyzed using Nanosight LM-14 instrument
(LCM14C, 405 nm laser, 60mW, Nanosight, Salisbury, Great Britain)
equipped with SCMOS camera (Hamamatsu Photonics K.K.,
Hamamatsu, Japan). The camera level was adjusted to 14, measure-
ment time for one acquisition was 90 s and every sample was analyzed
in triplicates. The results were analyzed using NanoSight NTA software
(NanoSight Ltd., v. 3.0) with detection threshold set to 5.
2.5. Cell lysate preparation
Cell lyste of PC-3 cells was prepared from a T75 cell culture flask of
PC-3 cells that were washed with ice-cold DPBS, followed by scraping
them in ice-cold RIPA lysis buffer (ThermoFisher Scientific) supple-
mented with protease inhibitor cocktail (Sigma Aldrich). The samples
were then incubated for 30min at +4 °C under agitation followed by
centrifugation with 16,000 g at +4 °C for 20min, collecting the re-
sulting supernatant.
2.6. Western blotting
The protein amount of EV samples prepared with iodixanol density
gradient and PC-3 cell lysate were standardized using Pierce™ BCA
protein assay kit (ThermoFisher Scientific) for the western blotting. A
total of 20 μg of protein was prepared by heating in Laemmli denaturing
sample buffer and ran with 4–20% Mini-PROTEAN® TGX™ Precast
Protein Gel (BioRad, Hercules, CA, USA). The proteins were then
transferred to a nitrocellulose membrane that was then blocked by in-
cubating it in 5% bovine serum albumin (BSA, Sigma Aldrich) in 0.1%
(v/v) TBS-Tween 20 (TBS-T) for one hour at room temperature under
agitation. The membrane was then cut into strips according to the
molecular weights of the proteins to be identified and the strips were
incubated in their respective primary antibody solutions overnight at
+4 °C under agitation. The primary antibody solutions (mouse anti-
TSG101, BD Biosciences, Frankling Lakes, NJ, USA and mouse anti-
Hsp70, BD Biosciences) were prepared in 5% BSA TBS-T by diluting
them 1:500. After the incubation the membranes were washed three
times in TBS-T, followed by incubation with HRP-conjugated secondary
anti-mouse antibody (ECL™ Anti-mouse IgG, GE healthcare, Little
Chalfont, UK) in TBS-T for one hour at RT. The membranes were then
washed again three times in TBS-T and once in TBS, followed by a 5min
incubation in ECL substrate solution (Clarity™ Western ECL Substrate,
BioRad) and imaged with BioSpectrum® imaging system (Ultra-Violet
Products, Cambridge, UK).
2.7. EV labeling and loading
The molecular structure of Ptx-OG (Tubulin Tracker Green™,
ThermoFisher Scientific, Massachusetts, USA) is presented in the
Supplementary Information (SI) Fig. S1. The 20 K MVs and 110 K EXOs
were labeled and loaded for FLIM imaging by adding 7.5 μl of 1 mM
Ptx-OG to one milliliter of 20 K MV/110 K EXO suspension (20 K MV/
110 K EXO particle concentration adjusted with DPBS to
1.5×1010 particles/ml), and by incubating the suspension protected
from light for 60min upon shaking at ambient temperature. Following
the incubation, the excess of Ptx-OG was removed by centrifuging once
with Optima MAX ultracentrifuge (MLA-130 rotor) at 110000 g for
180min, +22 °C. The 20 K MV/110 K EXO pellets were resuspended in
50 μl of DPBS before the application to the cells. Loading of the EVs
with Ptx-OG was estimated by ultra-performance liquid chromato-
graphy (UPLC, Acquity UPLC system, Waters, Massachusetts, USA),
UPLC column CORTECS™ C18+ 2.1× 50mm with pore size 2.7 μm
(Waters, Ireland). Flow rate was 0.5 ml/min. The sample injection vo-
lume was 5 μl. Gradient solution was phosphate buffer:acetonitrile with
40–80% of acetonitrile. Signal was detected at 290 nm with retention
time 2.6 s. Ptx-OG loaded EVs were pretreated with 1% Triton X-100
and centrifuged at 1000 g for 5min. Due to some losses of Ptx-OG
loaded EVs after purification and intentional providing of small label-
ling densities to avoid fluorescence self-quenching events the small
concentrations of Ptx-OG in EVs had fallen under the calibration curve
according to UPLC data. This made it impossible to calculate the exact
reliable values of the loading efficiencies. However, estimated loading
of the EVs was over 50% in both 110 K EXOs and 20 K MVs.
After the Ptx-OG labeling and loading, the MV membranes were
labeled with lipophilic DiD label (Biotium Inc., USA) for confocal
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imaging. 1 μl of DiD label was added to 1ml of MV suspension (1010
particles/ml) and incubated for 30min at +22 °C protected from light.
Unbound DiD label was removed by centrifugation as described above.
2.8. Cell sample preparation for FLIM
One day before the imaging procedure 75,000 PC-3 cells were in-
oculated to a glass bottom 35mm Petri dish, No. 0 coverslip, 10mm
glass diameter, coated with poly-D-lysine (MatTek, Massachusetts,
USA). Medium was changed 2 h before the imaging. Free Ptx-OG as well
as Ptx-OG loaded EVs were added into the medium of PC-3 cell culture
at the microscope stage directly before imaging of the first time points
(several minutes after the addition) followed by the further imaging for
24 h (Ptx-OG EVs) and 12 h (free Ptx-OG). A single cell was imaged
every 2 h until the end of the experiment or until the cell detached. As
the aim of the study was to monitor the trafficking of Ptx-OG and Ptx-
OG-labeled EVs in the cells, the excess of the label was not washed out
prior the FLIM measurements in contrast to the conventional sample
preparation for the confocal microscopy. This was possible as the signal
intensity in the cell area was incomparably high regarding the back-
ground intensity of the medium. Moreover, the area inside the cell was
selected as the region of interest (ROI) for the lifetime determination in
the obtained FLIM pictures allowing to exclude the background signal
from the analysis.
2.9. Fluorescence lifetime imaging microscopy (FLIM)
Fluorescence lifetime images were acquired using a fluorescence
lifetime microscope MicroTime-200 (PicoQuant, Germany) coupled to
the inverted microscope Olympus IX-71 (Olympus, Japan). FLIM with a
100×oil objective having NA 1.4 enabled a minimum spatial resolu-
tion of 300 nm and a maximum scan area of 80 μm×80 μm. The pulsed
laser diode LDH-P-C483 (PicoQuant, Germany) emitting at 483 nm
(time resolution 120 ps) was used for fluorescence excitation and the
emission was monitored using 510 nm long pass filter The cells also
were imaged with IDS uEye camera coupled to microscope. The
SymPhoTime 64 software was used to calculate the lifetime map
images. During imaging the living PC-3 cells were kept at 37 °C and at
5% CO2 using an objective heater (Bioscience Tools, California, USA,
TC-1-1005 Temperature Controller) and a custom-made incubator. In
FLIM images the colors are based on the mean intensity weigted life-
times < > = ∑ ∑τ I τ I( )/( )I i i i i i at each pixel. To gain more in formation
on the lifetime changes, a region of interest (ROI) was selected and the
corresponding fluorescence decay was extracted. The fluorescence
decay curves were fitted by applying iterative least-squares method to
the sum of exponents in the equation = ∑ −I t λ a λ e( , ) ( )i i
t τ/ i where τi is
the lifetime and αi(λ) is the amplitude (pre-exponential factor) and the
amplitude weighted average fluorescence lifetimes were calculated as
< > = ∑ ∑τ a τ a( )/( )α i i i i i (more about these two averaged lifetimes in SI
Fig. S2) [42].
In each imaging series multiple cells were followed and the total
number of imaged cells were 10 for Ptx-OG-20 K MVs and Ptx-OG-110 K
EXOs and 9 for free Ptx-OG. The fluorescence lifetimes τ1 and τ2 at each
time point (Fig. 4) are arithmetic means of the values calculated from
several cells. The error bars represent range error bars obtained as
τi
max− τi
min, where τimax and τimin are maximal and minimal lifetime
values at about the same time point i, respectively [62].
2.10. Confocal microscopy
The confocal microscopy studies were performed for the validation
and as a comparison for the FLIM studies. Ptx-OG trafficking to living
PC-3 cells as bound to EVs was explored using Leica SP5 HCS confocal
microscope (Leica, Germany) equipped with Leica DMI6000 B micro-
scope and DPSS 561 nm/20mW. Argon 488 nm/45mW and HeNe
633 nm/12mW lasers were used for fluorescence excitation with a
single-photon avalanche detector (SPAD) and hybrid detector (HyD)
used to detect the fluorescence. 45,000 PC-3 cells were inoculated in
each well of a glass bottom 24-well plate (MatTek, Ashland
Massachusetts, USA). The cell membranes and lysosomes were labeled
for imaging at ~70% confluency. In order to demonstrate the co-loca-
lization and release of Ptx-OG from the EVs uptaken by the cells, MVs
were labeled with lipophilic DiD label and loaded with Ptx-OG, and
imaged using confocal microscopy.
The cell membranes were labeled with CellMask Deep Red Plasma
membrane label. The stock solution of the membrane label was diluted
to cell culture medium in 1:1000, and 50 μl of the dilution was added to
the wells. The lysosomes and endosomes of the PC-3 cells were labeled
with Lysotracker Red (Invitrogen, California, USA) using a dilution of
1:1000 in culture medium and 50 μl of the dilution was added to the
wells. The cells were incubated with membrane and lysosome labels
simultaneously for 60min at 37 °C. After the incubation, the culture
medium was carefully aspirated and the wells were washed 2–3 times
with 0.5 ml of pre-heated culture medium. Lastly, either 400 μl of plain
culture medium, or 110 K EXOs or 20 K MVs suspended in culture
medium were added to the cells.
All confocal images were acquired using 20×objective and Leica
HCS A Matrix Screener software (Leica Microsystems, Germany) that
recorded images from the wells every 2 h over the 22 h observation
period. Every well was imaged at four different positions from 0 to 22 h,
and from 24 to 42 h after adding the EVs. LysoTracker Red was excited
using 581 nm wavelength, CellMask Deep Red Plasma (CM, cell mem-
branes) or DiD (alternative membrane label) using 633 nm, and Ptx-OG
using 488 nm. The cells were kept at 5% CO2 and 37 °C during the
imaging.
2D images were analyzed with Fiji software (an open source image
processing package based on ImageJ) to create 3D renditions of the
cells. The 3D images were processed with Imaris 7.7.2 software
(Bitplane AG, Switzerland). Briefly, in the 3D analysis the cells were
defined by formulating a surface using the CM channel, and the lyso-
somes with the LR channel. In the next stage, the average intensity of
Ptx-OG inside cells or lysosomes was calculated for each sample as a
function of time. As four locations were imaged in every well, an
average of the four sectors was calculated. In order to follow the release
of Ptx-OG from the microvesicles, a separate surface was defined for
DiD used to label microvesicles.
3. Results
Our model system comprised of prostate cancer cells (PC-3) and
their autologous EVs loaded with Ptx-OG. The EVs were characterized
using Western blot analysis and nanoparticle tracking analysis as de-
scribed in our earlier studies [30, 35]. The EVs were found to migrate to
iodixanol fractions in the range of 1.058–1.163 g/ml, which corre-
sponds to the density reported by others as well [63, 64]. While 20 K
MVs were found to be slightly larger on average, the size distributions
Table 1
Fluorescence lifetimes, τi, and in the case of two-exponential fluorescence decay
the proportion of the shorter-living component, a2, for Ptx-OG in different
systems.
Solution and hydrogel samples τ1 (ns) τ2 (ns) a2 (%)
Free Ptx-OG in DPBS (pH=7.0) 4.4 – –
Ptx-OG-EVs (both 20 K MVs and 110 K EXOs) in DPBS
(pH=7.0)
4.0 – –
Free Ptx-OG in NFC hydrogel in water 4.1 1.9 36
Ptx-OG-20 K MVs in NFC hydrogel in water 4.0 1.9 34
Ptx-OG-20 K MVs in NFC hydrogel + Triton X in water 4.3 1.9 21
Ptx-OG-110 K EXOs in NFC hydrogel in water 3.9 1.9 32
Ptx-OG-110 K EXOs in NFC hydrogel + Triton X in
water
4.1 2.1 20
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analyzed by NTA showed heavy overlapping between 20 K MV and
110 K EXO populations, with the mode diameter being approximately
200 nm in both (SI Fig. S3A). Therefore we conclude no meaningful
difference in the size profiles of 20 K MVs and 110 K EXOs. Western blot
analysis of TSG101 and Hsp70 showed that TSG101 appeared to be
slightly enriched in both EV populations compared to the cell lysate,
while Hsp70 is found significantly more in the cells (SI Fig. S3B). 110 K
EXO and 20 K MV populations seemed to express these two proteins at a
similar level. Taken together these results regarding the density, size
and TSG101 enrichment suggest the presence of EVs in our prepara-
tions, and that 20 K MVs and 110 K EXOs were very similar despite their
differences in sedimentation speeds. However, total protein con-
centration per vesicle for 110 K EXOs was 2–4 times higher than that for
20 K MVs, suggesting a clear difference in protein content of the studied
EV populations (SI Fig. S3C).
3.1. Ptx-OG fluorescence lifetimes in different environments
To be able to interpret the changes in OG fluorescence lifetime
during EV uptake and their intracellular trafficking, we measured the
fluorescence lifetimes of Ptx-OG in different systems (Table 1, SI Fig.
S4). In solution, the fluorescence of Ptx-OG and Ptx-OG labeled EVs was
one-exponential with lifetimes of 4.4 ns and 4.0 ns, respectively. To be
able to simulate Ptx-OG fluorescence lifetimes in a system, which re-
sembles the free physical situation when EVs are either on the cell
surface or in the cytosol, we made the same measurements in 1.5% of
Fig. 1. FLIM and light microscope images of the PC-3 cells at different times after the addition of free Ptx-OG. The brightness of each pixel in the FLIM images
correlates with the concentration of the fluorescent species in the corresponding spatial location. The color of each pixel in the FLIM images correlates with the
average fluorescence lifetime in the corresponding spatial location as follows: 2.0 ns 4.5 ns.
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nanofibrillar cellulose (NFC) hydrogel in water. It is now known, that
NFC hydrogel interaction with EVs is only mechanical and no chemical
interaction is present (data under submission). For free Ptx-OG and EV
bound Ptx-OG in NFC hydrogel the fluorescence decays were 2-ex-
ponential and the proportion of the shorter, about 1.9 ns, component
was about 34%. The lifetime of the longer living component was about
4.0 ns, corresponding to that of free Ptx-OG and Ptx-OG-EVs in solution.
The change from one-exponential decay in solution to two-exponential
in NFC hydrogel was probably a result of partial aggregation of Ptx-OG
molecules or Ptx-OG- EVs due to the higher viscosity of the environ-
ment [65] and thus reflects the behavior of Ptx-OG, EV-bound or free,
gathering to certain sites inside the cell. When Ptx-OG was released
from the EVs by a Triton X treatment (Table 1, SI Fig. S4), the pro-
portion of the shorter decay component decreased to about 20% in-
dicating that the environment of Ptx-OG changes closer to that in so-
lution.
3.2. FLIM reveals differences in cellular uptake mechanisms and functions
between 110 K EXO and 20 K MV populations
3.2.1. Free Ptx-OG
FLIM images for the free Ptx-OG taken at various time points and
the corresponding light microscope images are presented in Fig. 1. As a
hydrophobic molecule, free Ptx-OG gathers very efficiently to the cell
membrane: already 5min after adding Ptx-OG to the medium, some
cells showed intense Ptx-OG fluorescence (Fig. 1, red color,< τ >
I=4.0 ns). After passing through the cell membrane, Ptx-OG accu-
mulated to the microtubules of the cell (yellow color). Between 6 and
12 h after adding Ptx-OG to the medium the average fluorescence life-
time< τ > I decreased slightly from 3.9 ns to 3.6 ns (from yellow to
green) reflecting the changes taking place in the Ptx-OG environment.
3.2.2. Microvesicles
FLIM images for Ptx-OG at different time points are presented in
Fig. 2. Two different types of cell behavior were observed in all sam-
ples. For some cells, the 20 K MV up-take was more efficient leading to
higher fluorescence intensities (Fig. 2, high intensity cells). Due to slow
diffusion of Ptx-OG-20 K MVs through the medium, the fluorescence in
the cells was rather weak still at 1 h after Ptx-OG-20 K MV addition to
the medium. At this point< τ> I was 3.9 ns. At 2.5 h, the high intensity
cells showed intense red color of Ptx-OG-20 K MVs accumulated onto
the cell membrane. At 4.5 h the fluorescence intensity had doubled and
part of the Ptx-OG had already accumulated to the microtubules
(yellow color). At about 6 h after Ptx-OG-20 K MV addition, a change
was observed: a second fluorescent area with shorter fluorescence
lifetime (green color) started to emerge around the nucleus. In time, the
intensity of Ptx-OG fluorescence increased, and ca. 14 h after 20 K MV
addition the cells started to round and die.
For other cells, the low intensity cells, the 20 K MV up-take seemed
to be weaker: the fluorescence intensity stayed much (at least 4 times)
lower than in the high intensity cells and smaller part of Ptx-OG
gathered slowly to microtubules (orange and yellow color). The rest of
Ptx-OG spread unevenly to the cytosol (green color), probably attached
to any available membrane structures such as the endosomal network.
At about 10 h, the borders of the nucleus started to fade and the cells
started to die. For both types of cells, a fluorescent spot started to form
in the middle of the dark area i.e. close to nucleus surface. It was not
completely isolated from the other fluorescing areas and its< τ > I
was equal to that in the microtubules (yellow color). Thus, it probably
belongs to the microtubules network and could also be the centrosome.
3.2.3. Exosomes
FLIM images for the Ptx-OG (OG) are presented in the Fig. 3. In
contrast to MVs, all the cells behaved more or less similarly when in
contact with 110 K EXOs. At 1 h after addition of 110 K EXOs, they had
spread to the cell membrane and Ptx-OG was partially internalized. A
distribution of different fluorescence lifetimes (colors) was observed
reflecting the different phases of this process. The 110 K EXOs can ei-
ther fuse with the endosome membrane releasing Ptx-OG to the cytosol
or end up degraded in the lysosomes. Again, as in the case of 20 K MVs,
the released Ptx-OG gathered to microtubules (yellow color) and
membrane structures such as the endosomal network (green color). As
in the case of 20 K MVs, in most cells a yellow fluorescent spot started to
form in the middle of the nucleus. After about 10 h the cells start to
round and die.
3.3. Fluorescence lifetime analysis
In the cells, the fluorescence decays of Ptx-OG were two-exponential
for all the studied delivery systems. The amplitude ratios of the two
components, τ1 and τ2, stayed almost constant between 25 and 35% for
free Ptx-OG and Ptx-OG-20 K MVs. For the Ptx-OG-110 K EXOs, the
ratio of the shorter-living component decreased from 45% to 30% in the
Fig. 2. FLIM images of the PC-3 cells (high intensity cell on the left and low
intensity cell on the right) at different times after the addition of Ptx-OG loaded
20 K MVs. The brightness of each pixel in the FLIM images correlates with the
concentration of the fluorescent species in the corresponding spatial location.
The color of each pixel in the FLIM images correlates with the average fluor-
escence lifetime in the corresponding spatial location as follows: 2.0 ns
4.5 ns.
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first 12 h (Table 2). In calculating the < τ> α, these changes mostly
cancel out each other. However, when looking at the behavior of the
lifetime each decay component as a function of time (Fig. 4) clear
trends were observed. The longer-living component τ1 behaves simi-
larly for all studied systems (Table 2 and Fig. 4a). During the first 2 h,
while EVs gather to the cell membrane followed by uptake, τ1 reached
its maximal value of about 4.3 ns (Phase I, Fig. 4a). After this, during EV
trafficking and functioning inside the cells, τ1 decreased to 4.0 ns (Phase
II, Fig. 4a) and stayed constant or slightly increased after 12 h during
cell death (Phase III, Fig. 4a). For the shorter-living component τ2 a
clear difference between the different delivery systems was observed
(Fig. 4b). For free Ptx-OG and Ptx-OG-MVs in high intensity cells, τ2
behaved similarly decreasing from almost 3 ns to less than 2 ns during
the first 12 h (Phase I and II, Fig. 4b, squares and triangles). For Ptx-OG-
110 K EXOs and Ptx-OG-20 K MVs in low intensity cells, τ2 was nearly
constant at about 1.2–1.5 ns for the first hours after cell uptake (Phase
II, Fig. 4b, diamonds and inverted triangles). After 12 h τ2 started to
increase finally reaching 2.0 ns (Phase III, Fig. 4b, diamonds and in-
verted triangles). The τ2 increase coincides to the signs of cell death in
FLIM and light microscopy images and is assumed as an indication of
cell collapse. Different cells of the low intensity cell subpopulation
supplemented by Ptx-OG-20 K MVs died at different time points and
most of them were dead after 18 h. This was seen by gradual increase in
τ2 at time range from 10 to 18 h (Fig. 4b, inverted triangles). In turn,
110 K EXO encapsulated Ptx-OG led to rather sharp increase in τ2 be-
tween 12 and 15 h time points (Fig. 4b, diamonds) reflecting the faster
and more simultaneous cell death compared to 20 K MV encapsulated
drug. After 18 h, τ2 became constant in all the systems corresponding to
the cell death.
3.4. Confocal microscopy
In order to validate the FLIM approach, 110 K EXOs and 20 K MVs as
drug carriers were examined using conventional confocal microscopy.
Here CellMask Deep Red Plasma membrane label (excitation 633 nm)
and LysoTracker Red (LR, lysosome label, excitation at 581) served as
an alternative labels to acquire more in-depth comprehension on the
EV-mediated drug delivery. The 3D confocal images of PC-3 cells in-
cubated with Ptx-OG loaded 110 K EXOs and 20 K MVs are displayed in
Fig. 5.
Fig. 3. FLIM images of two PC-3 cells (cells A and B) at different times after the addition of Ptx-OG loaded 110 K EXOs. The brightness of each pixel in the FLIM
images correlates with the concentration of the fluorescent species in the corresponding spatial location. The color of each pixel in the FLIM images correlates with
the average fluorescence lifetime in the corresponding spatial location as follows: 2.0 ns 4.5 ns.
Table 2
Fluorescence lifetimes, τi, and in the case of two-exponential fluorescence decay
the proportion of the shorter-living component, a2, and amplitude weighted
average fluorescence lifetime,< τ> α, for Ptx-OG in different systems.
Cell samples Interaction time τ1 (ns) τ2 (ns) a2 (%) < τ > α
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Consistent with the FLIM results, we perceived that Ptx-OG loaded
into the EV carriers interacted with and was internalized into the PC-3
cells already after 2–3 h of adding the 110 K EXOs or 20 K MVs. Several,
but not all cells' microtubules were labeled until they died at ~20 h; this
phenomenon has been reported in our previous study [35]. Intrigu-
ingly, the confocal images on 20 K MVs demonstrated that Ptx-OG was
distributed more evenly on the membranes of PC-3 cells than 110 K
EXOs that exhibited spot-resembling distribution of Ptx-OG. This in-
dicates that MVs use primarily plasma membrane fusion mechanism
during the internalization whereas the main uptake mechanism for
110 K EXOs could be endosomal route. However, for both 110 K EXOs
and 20 K MVs some Ptx-OG fluorescence appeared to reside at the same
locations where LR exposed the lysosomes. These perceptions indicate
the existence of multiple overlapping cellular uptake mechanisms. Al-
though 20 K MVs mainly released Ptx-OG through the membrane fu-
sion, a proportion of them were apparently internalized via endocytic
pathways as they were seen to accumulate into the lysosomes. The
merged representation and differential interference contrast (DIC)
images finally illustrated the overall sequence of events showing that
the morphology of PC-3 cells changed towards circular-shaped and
intumescent. Finally, at the 42 h observation point all the examined
cells were dead.
4. Discussion
To elucidate the above presented results, the possible fates of Ptx
during the studied drug delivery processes is discussed taking into ac-
count the known pharmacological mechanism of Ptx presented in the
introduction. Three phases can be recognized from the different fluor-
escence lifetimes (Fig. 4) at specific localizations in the cell observed in
FLIM and the confocal microscopy results (Fig. 5). In phase I (0−2 h)
the EVs gather around the cells and interact with plasma membrane
followed by uptake – red color appears in FLIM images. In phase II
(2−12 h) EV trafficking and functioning takes place inside the cells –
yellow and green colors in FLIM images depending on the EV location
in the cell. In phase III (after 12 h) the cell death takes place – greenish
yellow color in FLIM images and clear morphology changes in the cells.
In order to label the microtubules, at least a proportion of Ptx-OG has to
be liberated from the 110 K EXO/20 K MV carrier whilst the inter-
nalization is ongoing. Since we observed microtubules network labeling
by Ptx-OG already after ~5 h of initiating the incubation of PC-3 cells
with 110 K EXOs/20 K MVs (Figs. 2 and 3, yellow color), we hypothe-
size that some amount of Ptx-OG diffuses out from the carriers almost
immediately at the beginning of PC-3 cell uptake. For Ptx-OG-20 K MVs
in PC-3 high intensity cells, the staining pattern at ~5 h resembles that
of free Ptx-OG suggesting that in high intensity cells direct fusion of
20 K MVs with the plasma membrane may dominate over endocytosis.
Leaking of Ptx from the EVs could be another interpretation for the
observed result. However, in our earlier studies no significant leakage
of Ptx from Ptx-EVs was detected after 24 and 48 h incubation at 37 °C
[35]. Interestingly, for 20 K MV carriers not all the microtubules were
labeled simultaneously, which might reflect paclitaxel's cell cycle spe-
cificity or multiple functions [66, 67]. Besides microtubules, Ptx can
also bind to an apoptosis-regulator protein called Bcl-2, inhibiting its
function, which can lead to apoptosis as well [66]. Bcl-2 is typically
found in the membranes of the nuclear envelope, endoplasmic re-
ticulum and mitochondria [68]. For Ptx-OG-110 K EXOs, once Ptx-OG
has been released from the 110 K EXOs to the cytosol, only part of it
accumulates onto microtubules (yellow color). The main part of Ptx-OG
delivered by 110 K EXOs shows shorter fluorescence lifetime (green
color) indicating that it has bound to another cellular target which
could be the apoptosis regulator Bcl-2, given that these cells die with
significantly different staining patterns compared to free Ptx-OG that
clearly stains microtubules. At about 12 h the morphology of the cells
start to change and the Ptx-OG fluorescence lifetime increases. This
could indicate the onset of apoptosis and the release of Ptx-OG from
Bcl-2. Taken together, the observations at (5–17 h) indicate that Ptx-OG
has been released from their 110 K EXO carriers and acting as expected,
initiates interaction with the microtubules network and/or with Bcl-2,
which ultimately leads to cell death [69, 70].
There is always some overlap on the size distributions of 110 K EXOs
and 20 K MVs and thus neither of these two up-take mechanisms for
Ptx-OG action can be completely ruled out for either of the carriers, but
exist in parallel. This is very clearly observed for 20 K MVs in PC-3 low
intensity cells: Ptx-OG acts very similarly to the 110 K EXO delivered
Ptx-OG. For 110 K EXOs in part of the cells (cell A in Fig. 3) fast
Fig. 4. Average fluorescence lifetimes a) τ1 and b) τ2 from two-exponential fits on the fluorescence decays obtained from the ROIs inside the cells in the FLIM images
of PC-3 cells as a function of time after addition of Ptx-OG (squares), Ptx-OG-EV (Ptx-OG-110 K EXOs – diamonds, Ptx-OG-20 K MVs –triangles for high intensity HI
cells and inverted triangles for low intensity LI cells) with range error bars. The solid lines indicate the behavior when endocytosis is suggested as main mechanism of
EV uptake and dashed line indicates the behavior when plasma membrane fusion of EVs or direct interaction of pure Ptx-OG with the membrane is suggested as the
main uptake mechanism. Three clear phases for behavior of the lifetimes were visible and are separated by vertical dashed lines: (I) EV gathering around the cells and
interaction with membrane followed by uptake (II) Intracellular EV trafficking and functioning, and (III) Cell death.
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accumulation to microtubules takes place. This could mean that part of
the 110 K EXOs fuse with the cell membrane and release Ptx-OG di-
rectly to the cytosol.
At the moment, the sub-cellular mechanism of Ptx induced cell
death remains partly speculative. More measurements with the Ptx
targets labeled with suitable fluorescent probes would be needed to
confirm the suggested scheme of events. However, the data presented in
here already shows us, that the two overlapping mechanisms of Ptx
induced cell death can be identified by FLIM studies and that the main
route depends on whether Ptx is administered via 110 K EXOs or 20 K
MVs.
5. Conclusions
Herein, we have demonstrated that FLIM is an effective method to
follow the EV-mediated drug delivery on intracellular level. Our data
illustrates that the internalization pathways of 110 K EXOs and 20 K
MVs are different and can be distinguished with this method. Subtle
Fig. 5. Confocal microscopic analysis of EV-mediated Ptx-OG delivery. Picture panel with 3D rendered confocal microscopy images of EV-mediated Ptx-OG delivery
process into PC-3 cells. PC-3 cells were treated with Ptx-OG carrying EVs, imaged using confocal microscopy every 2 h, and the localization of Ptx-OG inside the cells
and lysosomes was quantified using 3D analysis. Channels from left to right; cells labeled with CellMask Deep Red Plasma membrane label (CM, blue) with Ptx-OG
(green) loaded MVs or EXOs (CM & Ptx-OG), PC-3 cells' lysosomes labeled with Lysotracker Red (LR, red) and Ptx-OG loaded MVs or EXOs (LR & Ptx-OG), merge of
CM, LR & Ptx-OG channels (CM, LR & Ptx-OG), differential interference contrast (DIC) microscopy images. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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sub-cellular mechanisms of EV movements and the release of Ptx-OG
from EVs can be predicted by harnessing the changes in the excited
state lifetime of a fluorescent probe, which is sensitive to physical and
chemical changes in its microenvironment. All this information was
obtained from a single fluorescing species since instead of fluorescence
intensity fluorescence lifetime was used to analyze the data. Hence, we
envisage that FLIM provides a completely new method to obtain in-
depth insights into these aspects, and the obtained results may inspire
the experts in the EV field to discover other prospective uses for FLIM.
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